Crowdonomics
All companies
NeXtGen Biologics ™ logo

NeXtGen Biologics ™

Operating

NeXtGen Biologics, INC

Biotech · Biotech · Alachua, FL · Founded 2023

Woman-founded

Patented, FDA-cleared, novel wound-care technology | new skin in the game

Valuation cap ⓘ
$40.0M
As of Feb 2023 · from Reg CF Offering (2022) · a SAFE/note conversion ceiling, not a priced valuation
Total raised
$13,626,753
Crowd $239K · Private $13.4M · 14 rounds since 2014
Latest share price
$3.35
Private · Common Stock · Dec 2022 offering price · down round

Financials

FY2020–FY2023 · from SEC filings · hover any figure for its source
$0
−$791K
2020
$0
−$2.5M
2021
$184K
−$1.7M
2022
$0
−$2.5M
2023
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2020 audited*
FY2021 unaudited
FY2022 unaudited
FY2023 audited
Income statement
Revenue
$0
$0
$183,814
$0
Cost of goods sold
$0
$0
$0
$0
Gross margin
—
—
100%
—
Net income
-$790,983
-$2,538,610
-$1,710,186
-$2,538,610
Taxes paid
$51,772
$0
$0
$0
Balance sheet
Cash
$516,897
$247,959
$488,382
$247,959
Accounts receivable
$0
$0
$134,214
$0
Total assets
$2,069,171
$1,926,991
$1,969,512
$1,926,991
Short-term debt
$9,110,917
$10,323,083
$1,189,767
$10,323,083
Long-term debt
$155,400
$3,165,969
$9,960,241
$3,165,969
Total liabilities
$9,266,317
$13,489,052
$11,150,008
$13,489,052
Other
Headcount
—
9
10
10

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$27.5M
est. pre-money
$40.0M
Valuation cap
Private · Common · Dec 2022
Reg CF · SAFE · Sep 2022

Dotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher. Dashed amber bars are a SAFE or convertible note's valuation cap — the most it converts at, not what the company is worth, so don't compare them with the other bars.

Share price over rounds

log scale
$693.6337$23.5565$0.80
Nov 20152023
Round offering price or verified disclosed saleDisclosed sale, unverified or year-onlyDown round · Dec 2022 (-99.5%)

Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.

Cap table

Share counts as of Dec 31, 2022
ClassOutstandingVotes / shareShare of totalLast price
common stock8,196,9851100.0%$3.35Dec 2022

Shares outstanding over timein today's share terms

8.2M4.1M0
May 2014Dec 2022
common stockRound openedSplit / conversion

Sold to the crowd

From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.

Fundraising history

Raised $130KInvestors 3
Reg CF · SAFE · Sep 2022Closedvia Republic
Raised $238.6K / $5MInvestors 347Valuation cap $40M
Raised $2.6MEst. pre-money $27.5M
Raised $100KInvestors 1
Raised $2.2MInvestors 19
Raised $500KInvestors 2

Team

7 people
Jonelle Toothman
Director, Chief Executive Officer, President and Secretary
Brian Lipke
Director
Daniel Hamister
Director
Elad Levy
Director
Gerald Kluft
Director
Jamie Grooms
Director
Sherrick Wassel
Director

Names and titles as disclosed on SEC Form C. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Delinquent

Filed 1 of 4 annual reports (FY2022–FY2025)

Missing: 2022, 2024, 2025

347 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

  • Form DSep 22, 20250001620524-25-000007
    EDGAR
  • Form C-AR/AApr 29, 20240001620524-24-000004
    EDGAR
  • Form C-ARApr 3, 20240001620524-24-000001
    EDGAR
  • Form C-UMar 10, 20230001796106-23-000001
    EDGAR
  • Form CSep 2, 20220001620524-22-000002
    EDGAR
  • Form DAug 17, 20200001620524-20-000001
    EDGAR
  • Form DDec 27, 20180001415889-18-001836
    EDGAR
  • Form D/AMay 24, 20170001620524-17-000001
    EDGAR
Source: ManualCIK 0001620524DEShare price $3.35

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.